Analysis Pymaceutical Inc.

The Analysis of Pymaceuticals’ drug of interest, Capomulin shows great promise when looking at tumor volume mean, median, and mode over the course of 45 days. Something that shows an even greater promise is the variance is significantly lower, which shows the medication Capomulin is consistently better than the rest. The next best would be ramicane which shows a strong decrease in the tumor through the 45 days as well. Not only are Capomulin and Ramicane showing the best results, but they are tested on the largest population of mice adding to the externally validity of the drug.